Quantcast

Latest Non-nucleoside reverse transcriptase inhibitors Stories

2010-06-17 12:42:54

Findings in Botswana study suggest women taking antiretroviral drug combinations can breastfeed safely An international clinical trial led by researchers at the Harvard School of Public Health (HSPH) has found that AIDS-fighting antiretroviral drug combinations given to pregnant and breastfeeding women in Botswana, Africa, prevented 99% of the mothers from transmitting the human immunodeficiency virus (HIV) to their infants. "This is the lowest rate of mother-to-child transmission recorded in...

2010-02-16 09:10:28

A new international study reported in PLoS Medicine confirms that a single dose of nevirapine (sdNVP) can lead to HIV treatment failure in women who receive the drug to prevent transmission of the AIDS virus to their infants. However, the increased risk of failure could only be detected in women who began full HIV treatment within about a year after receiving sdNVP. Because of its convenience and availability, sdNVP has become the mainstay for preventing mother-to-child transmission (MTCT) of...

2010-01-04 08:28:00

WALTHAM, Mass., Jan. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in 2018, the fixed dose coformulation of Tibotec's* rilpivirine and Gilead's Truvada will achieve blockbuster sales of more than $2 billion in the HIV drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. The Pharmacor finding from the topic entitled Human Immunodeficiency Virus...

2009-10-27 12:08:39

Press release from PLoS Medicine In a clinical trial investigating mother-to-child HIV transmission in South Africa published this week in PLoS Medicine, Neil Martinson (of the Perinatal HIV Research Unit, Soweto, South Africa) and colleagues find that adding two other antiretroviral drugs to single dose nevirapine "“ an antiretroviral drug given to women and newborn children during labor and delivery to prevent transmission "“ is effective in reducing the drug resistance that...

2009-07-20 07:00:00

CAPE TOWN, South Africa, July 20 /PRNewswire/ -- New data became available today at the 5(th) International AIDS Society Conference from ARTEN (Atazanavir/Ritonavir on a background of Tenofovir and Emtricitabine [Truvada(R)] versus Nevirapine). ARTEN is an open-label, multi-center and international non-inferiority clinical trial. It is the first large study to directly compare the efficacy and safety of nevirapine and ritonavir-boosted atazanavir (ATV/r) when combined with TDF/FTC, a...

2009-01-06 11:33:23

Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report. But the investigators highlight the proven superiority of the six-week regimen in preventing mother-to-child HIV transmission in breast-fed infants.In a study led by researchers at Johns Hopkins Children's Center, risks of drug...

2008-10-27 09:00:41

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that additional data from a Phase 2a monotherapy study of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of human immunodeficiency virus (HIV), were presented at the 48th Annual ICAAC/IDSA 46th Annual Meeting in Washington, DC. Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, gave an oral presentation showing that in the Phase 2a study, RDEA806...

2008-10-23 06:00:27

Although once praised for its efficacy even in highly treatment-experienced patients, Fuzeon's high cost and cumbersome mode of administration have restricted its overall growth. Driven by the launch of three new orally available and relatively inexpensive drugs, global sales of Trimeris' HIV drug have now dropped by 38% in the third quarter of 2008. Trimeris announced worldwide net sales of its HIV entry inhibitor Fuzeon for the third quarter of 2008 were $45.5 million, down 38% from $73.9...

2008-10-20 09:00:42

Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that the United States Patent and Trademark Office has issued a patent covering the composition of matter of RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of patients with human immunodeficiency virus (HIV), and related analogs. U.S. Patent No. 7,435,752 was issued on October 14, 2008. "We are very pleased with the continued expansion of our proprietary position in the NNRTI area....

2008-08-07 15:00:12

MEXICO CITY and SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. today announced that data was presented from its completed Phase 2a proof-of-concept monotherapy study of RDEA806, the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV), demonstrating robust antiviral activity with a well-tolerated profile. An oral presentation of the data was given today by Dr. Graeme Moyle, Director...


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related